Rough sledding ahead for Obamacare in the Senate.

“They know they don’t have 60 votes,” said former Senator John Breaux, who now heads a lobbying firm that represents the Pharmaceutical Research and Manufacturers of America, the drug industry’s Washington trade group. “They have to go back to the drawing board” on the plan to set up a government-run insurer, he said.